Robert Weisman

Weisman covers the healthcare and life sciences industries for the Business section. He was a business reporter and editor for the Hartford Courant and the Seattle Times before joining the Globe in 2000.

Latest stories

Baxalta shares up on report that Shire may sweeten its $30 billion bid

By , Globe Staff

Shares of biopharma company Baxalta Inc. rose Wednesday morning as investors gauged a report that Shire PLC may be readying a sweetened takeover bid for Baxalta.

While Big Pharma gets bigger, local biotechs innovate

By , Globe Staff

Overshadowed by the Pfizer-Allergan merger was a much smaller deal that highlights what makes the Mass. biotech industry tick.

Pfizer’s deal with Allergan a test for ‘tax inversions’

By , Globe Staff

The $160 billion buyout of Allergan would lower the US drug giant’s tax bill by turning it into an Irish-based company.

Five things you should know about Terry McGuire

By , Globe Staff

McGuire, founding partner of Polaris Partners, has invested in four dozen businesses over the past three decades.